Proactive Investors - Run By Investors For Investors

Generic drugs giant Teva sinks after second quarter earnings disappoint, full-year guidance slashed

Teva reported an 18.4% drop in second quarter earnings to US$1.02 per share excluding one-off items
generic pills
Rumours circulated last month that Teva was lining up AstraZeneca boss Pascal Soriot to take over as chief executive

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) saw its share price plummet in pre-market trading after the generic drugs giant missed second quarter expectations and cut its full-year outlook.

Weaker prices in the States meant Teva reported an 18.4% drop in second quarter earnings to US$1.02 per share excluding one-off items (Q2 2016: US$5.7bn).

The weaker profitability came despite the group generating revenues of US$5.7bn, ahead of the US$5.04bn it posted last year and beating consensus expectations of US$5.68bn.

Revenue from the generics business came in at US$3.08bn, just below the US$3.12bn analysts had originally pencilled in.

Forecasts cut, divi lowered and jobs to be axed

The poor performance meant Teva cut its adjusted earnings per share outlook to US$4.30 – US$4.50 from US$4.90 – US$5.30

Interim chief executive Yitzhak Peterburg said the drugmaker was now focused on implementing “meaningful cost reductions”, with reports suggesting that it will axe 7,000 jobs by the end of the year.

Speaking of axes, the quarterly dividend pay-out was also chopped by 75% to US$0.085 per share, compared to US$0.34 for the same period last year.

Shares were already down by almost a quarter in 2017 alone, and they dived by another 17.4% in pre-market trade to US$25.80.

View full TEVA profile View Profile

Teva Pharmaceutical Industries Timeline

Related Articles

Vial of pills
June 25 2018
Cosmos is a modern company, but the trade routes it relies on are ancient
March 15 2018
Amryt's lead drug candidate, AP101, is a potential treatment for epidermolysis bullosa, a rare genetic skin disorder for which there is currently no approved treatment
picture of cannabis plants
March 23 2018
Control of the supply chain offers operational advantages and financial benefits.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use